×
Aptorum Group EBITDA 2018-2024 | APM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Aptorum Group ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Aptorum Group EBITDA 2018-2024 | APM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Aptorum Group ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$70.1B
Zoetis (ZTS)
$68.6B
Takeda Pharmaceutical (TAK)
$47.3B
Daiichi Sankyo, - (DSNKY)
$46.4B
BeOne Medicines - (ONC)
$33.9B
Sandoz Group AG (SDZNY)
$27.3B
Summit Therapeutics (SMMT)
$20B
Merck (MKKGY)
$16.3B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.9B
Neurocrine Biosciences (NBIX)
$13.6B
Orion OYJ (ORINY)
$11.3B
IPSEN (IPSEY)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$9.4B
Eisai (ESAIY)
$9.2B
Corcept Therapeutics (CORT)
$7.3B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$2.1B
Dyne Therapeutics (DYN)
$1.9B